Trial Profile
A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs CP 101 Finch Therapeutics Group (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PRISM 3
- Sponsors Crestovo; Finch Research & Development
- 31 Mar 2022 According to a Finch Therapeutics Group media release, data will be presented at Digestive Disease Week (DDW) 2022.
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 27 Oct 2021 Results assessing CP101 engraftment drives efficacy for prevention of recurrent C. difficile Infection, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.